AOD-9604 Explained: What the Research Says and Its ARTG Status
Published 19 September 2026
AOD-9604 Explained: What the Research Says and Its ARTG Status
Updated September 2026
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone that has been investigated for its metabolic and lipolytic properties. Unlike many newer peptides discussed online, AOD-9604 has a relatively long research history, including preclinical studies and human clinical development. However, a history of research and clinical trials should not be confused with regulatory approval. This article explains what AOD-9604 is, what the published research has investigated, and how its regulatory status in Australia differs from that of an ARTG-registered medicine. (Ng et al., 2000; Wilding, 2004; Therapeutic Goods Administration, 2015).
What is AOD-9604?
AOD-9604 is a synthetic peptide based on the C-terminal portion of human growth hormone. Research published by investigators at Monash University described AOD-9604 as a synthetic analogue of the lipolytic domain of human growth hormone and investigated its metabolic effects in animal models. (Ng et al., 2000).
The early research focused on whether AOD-9604 could influence fat metabolism without reproducing all of the effects associated with full-length human growth hormone. In animal studies, researchers observed effects including increased fat oxidation and changes in lipolytic activity. These findings were preclinical and cannot, by themselves, establish that the same effects occur in humans. (Ng et al., 2000; Heffernan et al., 2001).
Why has AOD-9604 attracted research interest?
The original scientific interest in AOD-9604 was largely related to its potential effects on fat metabolism. Preclinical studies investigated whether the peptide could influence body-weight gain, fat oxidation and lipolysis in animal models. These studies provided a basis for subsequent investigation in humans. (Ng et al., 2000; Heffernan et al., 2001).
Importantly, animal findings should not be interpreted as evidence that a medicine is effective or appropriate for human weight management. Preclinical research is one stage of drug development, while evidence of clinical effectiveness requires appropriately designed human studies. (Therapeutic Goods Administration, 2026).
AOD-9604 and human clinical research
AOD-9604 progressed beyond laboratory research into human clinical development. A 2004 review reported that Phase IIa clinical trials were underway as part of development of AOD-9604 for potential obesity treatment. This demonstrates that the substance was investigated clinically, but clinical investigation itself does not constitute regulatory approval. (Wilding, 2004).
The distinction between clinical research and regulatory approval is important. A substance can be investigated in clinical trials without subsequently becoming an approved medicine. Approval requires a regulatory assessment of the relevant evidence and a decision that the therapeutic good meets the applicable requirements for registration. (Therapeutic Goods Administration, 2024).
What does the research actually tell us?
The published literature provides evidence that AOD-9604 has been investigated in both preclinical models and human development programs. However, the existence of research does not establish that AOD-9604 is an approved or established treatment for weight management or another particular medical condition. The strength of evidence must be considered according to the study design, population, route of administration, endpoints, duration and overall body of evidence. (Ng et al., 2000; Wilding, 2004; Therapeutic Goods Administration, 2026).
This distinction is particularly relevant when information about peptides is presented online. A laboratory study, animal study, early-phase clinical trial or historical development program should not automatically be presented as evidence that a peptide is safe, effective or appropriate for a particular individual. (Therapeutic Goods Administration, 2026; Ahpra, 2026).
Is AOD-9604 approved in Australia?
AOD-9604 is not currently included in the ARTG as an approved medicine. The Australian Register of Therapeutic Goods is the TGA’s public database of therapeutic goods that may legally be supplied in Australia, subject to the relevant legislative requirements and exemptions. Being absent from the ARTG means that AOD-9604 should not be described as an ARTG-registered or TGA-approved medicine. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2021).
It is important to distinguish this regulatory position from the fact that AOD-9604 has been the subject of scientific and clinical research. Research history does not itself create an ARTG registration, and a substance’s inclusion in the scientific literature does not mean that the TGA has approved it for therapeutic use. (Therapeutic Goods Administration, 2024).
What is AOD-9604’s Schedule 4 status?
AOD-9604 was included in Schedule 4 of the Poisons Standard following a TGA scheduling decision in 2015. Schedule 4 is the prescription-only category within the Poisons Standard and reflects a requirement for appropriate professional oversight; importantly, scheduling is separate from ARTG registration and does not mean that a substance has been approved for a particular therapeutic indication. (Therapeutic Goods Administration, 2015).
The 2015 TGA scheduling material also identified limitations in the available safety information, including limited data concerning repeated intravenous or subcutaneous administration and longer-term oral use at doses exceeding those investigated in clinical trials. Historical scheduling information therefore provides useful regulatory context but should not be interpreted as a current clinical assessment of an individual’s suitability for AOD-9604. (Therapeutic Goods Administration, 2015).
What is the difference between Schedule 4 and ARTG approval?
These two concepts are sometimes confused.
Schedule 4 describes how a substance is classified under the Poisons Standard and the level of access control that applies to it. ARTG registration, on the other hand, relates to a particular therapeutic good being included in the Australian Register of Therapeutic Goods for lawful supply under the applicable regulatory framework. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2015).
Therefore, the fact that AOD-9604 is Schedule 4 should not be interpreted as meaning that AOD-9604 is an approved weight-management medicine in Australia. Scheduling and registration are separate regulatory concepts. (Therapeutic Goods Administration, 2015; Therapeutic Goods Administration, 2024).
What does “unapproved therapeutic good” mean?
The TGA describes unapproved therapeutic goods as goods that have not been included in the ARTG and therefore have not undergone the TGA’s standard pre-market assessment for safety, quality and efficacy that applies to approved therapeutic goods. Australian legislation provides specific pathways under which certain unapproved therapeutic goods may be accessed in defined circumstances. (Therapeutic Goods Administration, 2026).
The existence of an access pathway for an unapproved therapeutic good does not change its regulatory status. An unapproved medicine remains unapproved, and access under a particular regulatory pathway should not be represented as equivalent to TGA approval or ARTG registration. (Therapeutic Goods Administration, 2026).
What role does a healthcare practitioner have?
Where an unapproved or compounded medicine is being considered, the relevant clinical decisions belong to the appropriately qualified and authorised healthcare practitioner responsible for the patient’s care. Ahpra guidance emphasises that prescribing an unapproved medicine requires appropriate clinical reasoning, consideration of evidence, informed consent and documentation of the decision-making process. (Ahpra, 2026).
Ahpra’s published case studies specifically address the prescribing of unapproved peptides. They highlight the importance of establishing a clinical reason for using an unapproved medicine, considering appropriate evidence, explaining that the medicine is unapproved, discussing potential risks, unknowns and alternatives, and documenting consent and clinical reasoning. (Ahpra, 2026).
Does compounding mean a medicine is TGA approved?
No. Compounding and ARTG registration are different regulatory concepts. The TGA states that compounded medicines are not evaluated individually for safety, quality or efficacy in the same way as registered medicines. Certain compounded medicines may be supplied under specific exemptions and conditions, but this does not make the compounded product an ARTG-registered medicine. (Therapeutic Goods Administration, 2026).
The circumstances in which a compounded medicine may lawfully be prepared and supplied are subject to applicable Commonwealth, state and territory requirements, as well as professional obligations applying to the practitioners involved. (Therapeutic Goods Administration, 2026; Ahpra, 2024).
Can AOD-9604 be advertised to the public?
Australian advertising rules are particularly important for prescription-only substances and unapproved therapeutic goods. The TGA states that advertising prescription medicines to the public is prohibited except in very limited circumstances, and its guidance specifically identifies Schedule 4 substances as prescription medicines for these purposes. (Therapeutic Goods Administration, 2026).
The TGA also states that advertising compounded medicines to the public is restricted and, in many circumstances, prohibited where the compounded product is a prescription medicine or an unapproved therapeutic good. Educational material therefore needs to be carefully distinguished from promotional material. (Therapeutic Goods Administration, 2026).
For this reason, information about AOD-9604 should not be presented as a recommendation to use the substance, a representation that it is effective for a particular condition, or an invitation to obtain an unapproved medicine. The regulatory status, research history and limitations of the evidence can be discussed separately from any clinical decision about an individual patient. (Therapeutic Goods Administration, 2026; Ahpra, 2026).
AOD-9604: research versus regulatory status
The easiest way to understand AOD-9604 is to keep three separate questions in mind:
| Question | What the evidence and regulation show |
|---|---|
| Has AOD-9604 been researched? | Yes. It has been investigated in preclinical studies and progressed into human clinical development. (Ng et al., 2000; Wilding, 2004). |
| Is AOD-9604 an ARTG-approved medicine? | No. It is not currently included in the ARTG as an approved medicine. (Therapeutic Goods Administration, 2024). |
| Is AOD-9604 scheduled in Australia? | AOD-9604 was included in Schedule 4 of the Poisons Standard by the TGA’s 2015 scheduling decision. (Therapeutic Goods Administration, 2015). |
| Does research establish that it is an approved treatment? | No. Research activity and regulatory approval are separate matters. (Therapeutic Goods Administration, 2024). |
| Does compounding make an unapproved medicine approved? | No. Compounding does not itself create ARTG registration or TGA approval. (Therapeutic Goods Administration, 2026). |
Frequently Asked Questions
Is AOD-9604 approved in Australia?
No. AOD-9604 is not currently included in the ARTG as an approved medicine. Its inclusion in scientific research and its Schedule 4 classification should not be confused with ARTG registration. (Therapeutic Goods Administration, 2015; Therapeutic Goods Administration, 2024).
Has AOD-9604 been studied in humans?
Yes. AOD-9604 progressed into human clinical development, with published literature documenting its development as a potential treatment for obesity. However, having been studied in humans does not mean that a medicine has demonstrated sufficient evidence for regulatory approval. (Wilding, 2004).
Is AOD-9604 the same as human growth hormone?
No. AOD-9604 is a synthetic peptide based on a fragment of human growth hormone rather than the complete growth hormone molecule. Research has investigated whether this fragment produces particular metabolic effects without reproducing all of the biological activity of full-length growth hormone. (Ng et al., 2000; Heffernan et al., 2001).
Does AOD-9604 research prove that it causes weight loss in humans?
No conclusion of that kind should be drawn simply from the existence of research. Preclinical studies and clinical development programs provide different levels of evidence, and regulatory approval requires assessment of the total evidence for the relevant therapeutic use. (Ng et al., 2000; Wilding, 2004; Therapeutic Goods Administration, 2024).
Does Schedule 4 mean AOD-9604 is TGA approved?
No. Schedule 4 classification and ARTG registration are separate regulatory concepts. A substance can be scheduled under the Poisons Standard without being an ARTG-registered medicine for a particular therapeutic indication. (Therapeutic Goods Administration, 2015; Therapeutic Goods Administration, 2024).
Does compounding make AOD-9604 an approved medicine?
No. The TGA states that compounded medicines are not individually assessed for safety, quality and efficacy in the same manner as ARTG-registered medicines. Specific exemptions can apply to the lawful supply of compounded medicines, but those exemptions do not constitute product approval. (Therapeutic Goods Administration, 2026).
Why is it important to distinguish research from approval?
A substance may have laboratory studies, animal studies or human clinical trials without becoming an approved medicine. Separating the scientific evidence from the regulatory status helps prevent research findings from being presented as proof of safety, efficacy or approval. (Therapeutic Goods Administration, 2024; Ahpra, 2026).
Key takeaway
AOD-9604 has a documented history of scientific investigation, including Australian research and human clinical development. It is also subject to prescription-only scheduling in Australia. However, research history, Schedule 4 classification and ARTG approval are three different things. AOD-9604 is not currently an ARTG-approved medicine, and information about its research should therefore be considered separately from any individual clinical decision. (Ng et al., 2000; Wilding, 2004; Therapeutic Goods Administration, 2015; Therapeutic Goods Administration, 2024).
Educational disclaimer
This article is provided for general educational and informational purposes only. It is not medical advice and does not constitute a recommendation, endorsement or representation that AOD-9604 is safe, effective or appropriate for any particular person or purpose. Information about research should not be interpreted as evidence of regulatory approval. (Therapeutic Goods Administration, 2024; Ahpra, 2026).
Clinical decisions concerning medicines, including unapproved or compounded medicines, are matters for appropriately qualified and authorised healthcare practitioners acting within their professional scope and applicable Australian law. Ahpra guidance emphasises evidence-based clinical reasoning, informed consent, documentation and ongoing professional responsibility when unapproved or compounded medicines are considered. (Ahpra, 2026; Ahpra, 2024).
References
- Australian Health Practitioner Regulation Agency (Ahpra) (2024) Joint statement on professional responsibilities for prescribing and dispensing medicines. View the Ahpra joint statement
- Australian Health Practitioner Regulation Agency (Ahpra) (2026) Meeting your professional obligations when prescribing off-label, unapproved or compounded medicines: Case studies. View the Ahpra case studies
- Heffernan, M. et al. (2001) ‘The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice’, Endocrinology, 142(12), 5182–5189. View the PubMed record
- Ng, F.M. et al. (2000) ‘Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone’, Hormone Research, 53(6), 274–278. View the PubMed record
- Therapeutic Goods Administration (2015) Reasons for scheduling delegate’s final decisions — March 2015. View the TGA scheduling decision (PDF)
- Therapeutic Goods Administration (2024) About the Australian Register of Therapeutic Goods (ARTG). View the TGA ARTG page
- Therapeutic Goods Administration (2026) Compounded medicines. View the TGA compounded medicines guidance
- Therapeutic Goods Administration (2026) Complying with the restrictions on advertising prescription medicines to the public. View the TGA advertising guidance
- Wilding, J. (2004) ‘AOD-9604 Metabolic’, Current Opinion in Investigational Drugs, 5(4), 436–440. View the PubMed record
Related reading
A note on this article
This article is general educational information only. It is not medical advice, and it is not a representation that any substance is safe, effective or approved for any purpose. It is not intended to promote the use, purchase or supply of any therapeutic good. Substances that have not been evaluated by the TGA carry unknown risks, including possible side effects, interactions with other medicines and unknown long-term safety.
GL Vitality Drips is a consultation coordination and administrative support service. We do not diagnose, treat, or prescribe, and GL Vitality Drips does not provide, supply, or grant access to any therapeutic good. Any consultation, assessment or pharmacy dispensing is arranged solely by independent, registered healthcare practitioners and licensed Australian pharmacies, subject to their own eligibility criteria. Not all individuals will be suitable candidates, and no outcome is guaranteed.
